This diagnostic assay utilizes Fe(II)-chelated alginate nanoparticles engineered via an inverse emulsion method and stabilized by crosslinking with gelatin. Upon exposure to urine samples containing MMP2/9 enzymes, the gelatin matrix is enzymatically cleaved, releasing individual iron-bound alginate particles. Subsequent acidification liberates Fe(II) ions, which then induce a Fenton reaction with chromogenic substrates, producing a distinct color change. This simple, point-of-care readout is achieved without the need for sophisticated equipment, and the assay maintains room temperature stability, ensuring its suitability in diverse clinical and resource-limited settings.
Description
What sets this technology apart is its unique integration of advanced nanomaterial synthesis with an instrument-free diagnostic protocol, achieving high sensitivity and specificity for bladder and prostate cancer detection. The method’s capacity to detect gelatinase activity at extremely low concentrations (1 pg/mL) in under 30 minutes highlights its analytical strength. Moreover, its cost-effective design and compliance with WHO’s ASSURED guidelines position it as a transformative alternative to traditional cancer diagnostics, filling a critical gap in rapid, accessible healthcare solutions.
Applications
- Point-of-care cancer diagnostics
- Urine-based cancer screening
- Rapid enzyme activity assay
- Low-cost diagnostic assay
Advantages
- High sensitivity and specificity for detecting bladder and prostate cancers
- Instrument-free operation suitable for point-of-care and resource-limited settings
- Rapid results in under 30 minutes
- Room temperature stability ensures ease of storage and transport
- Cost-effective implementation reducing overall diagnostic expenses
IP Status
https://patents.google.com/patent/US11061033B2
